Syndax to Present at the Cowen 39th Annual Health Care Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR
March 8, 2019 6:57 AM ESTB.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.
On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1... More
